Pomerantz Law Firm Investigates Allegations Against Argenx SE Following FDA Alert

Pomerantz Law Firm Investigates Allegations Against Argenx SE

In a significant development for investors in argenx SE, the Pomerantz Law Firm has announced its investigation into potential securities fraud claims on behalf of shareholders of the biopharmaceutical company listed on NASDAQ under the ticker ARGX. This investigation comes in light of recent troubling news regarding one of argenx's key products, Vyvgart Hytrulo.

On June 30, 2025, the U.S. Food and Drug Administration (FDA) released a warning that has raised concerns about the safety of Vyvgart Hytrulo. The alert indicated that there may be serious risks associated with the treatment, specifically pointing to a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy." This warning was based on data gathered through the FDA's Adverse Event Reporting System, which collects reports of any adverse or unintended effects following the use of medications.

As a result of the FDA alert, shares of argenx experienced a notable decline, dropping $8.92, or 1.59%, closing at $551.22 per American Depositary Share (ADS) on the same day. This drop reflects growing investor concern regarding the implications of regulatory scrutiny and potential actions that the FDA may take in response to the findings linked to Vyvgart Hytrulo.

The Pomerantz Law Firm is urging investors who have been negatively impacted to reach out. Danielle Peyton, a representative from the firm, is available for contact at [email protected] or by phone at 646-581-9980, ext. 7980. The firm is dedicated to assessing whether argenx and its officers may have engaged in deceptive practices or misled shareholders regarding the product’s safety and efficacy.

Pomerantz LLP boasts a distinguished history in the legal landscape, particularly in the realm of corporate and securities class actions. Established over 85 years ago by the late Abraham L. Pomerantz, a pioneer in the field, the firm has successfully represented numerous victims of securities fraud and corporate misconduct. With offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues its commitment to fighting for shareholder rights and holding corporations accountable for breaches of fiduciary duties.

While the investigation moves forward, the implications for argenx SE could be substantial depending on the outcomes. Any findings that confirm allegations of securities fraud or misrepresentation may lead to increased financial liability for the company, as well as potential changes in leadership or corporate governance practices.

Investors are advised to stay informed about developments regarding argenx and the ongoing FDA review, as the safety and regulatory status of Vyvgart Hytrulo will likely impact the company’s market performance significantly. Pomerantz is poised to act on behalf of its clients to ensure that any unjust practices are addressed appropriately in the court of law.

As the investigation unfolds, this case highlights the critical importance of transparency and the ethical obligations corporations have to their investors and the public. The outcome of this inquiry could set significant precedents in the realm of biopharmaceuticals and investor securities, reinforcing the need for companies to maintain honesty and integrity in their communication and reporting.

In conclusion, investors who have suffered losses due to the recent developments surrounding argenx SE's products should consider consulting with legal experts to evaluate their options. As the investigations proceed, it will be essential for the financial markets to remain vigilant and for corporate practices to evolve in response to regulatory and ethical standards.